Allergy Therapeutics PLC Annual Report and AGM Notification (4127O)

TIDMAGY

RNS Number : 4127O

Allergy Therapeutics PLC

07 October 2021

7 October 2021

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

ANNUAL FINANCIAL REPORT 2021 AND NOTICE OF 2021 ANNUAL GENERAL MEETING

Allergy Therapeutics plc has today published the following documents:

   --      Annual Report and Accounts for the year ended 30 June 2021 ("Annual Report"); and 
   --      Notice of 2021 Annual General Meeting ("Notice of Meeting"); 

Each of these documents is available electronically on the Company's website at www.allergytherapeutics.com

A hard copy of the Annual Report and Notice of Meeting has been posted to shareholders on 6 October 2021.

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

[phone]

Freddy Crossley / Emma Earl / Mark Rogers, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Davide Salvi

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved 10% compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFVEIELDIIL

(END) Dow Jones Newswires

October 07, 2021 11:37 ET (15:37 GMT)